Ionis and Recordati Enter Exclusive License Agreement for Zilganersen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Exclusive License Agreement: Ionis has entered into a licensing agreement with Recordati, granting Recordati exclusive rights to develop and commercialize zilganersen outside the U.S., while Ionis retains commercial responsibility in the U.S., indicating a strategic global market positioning for Ionis.
- FDA Review Progress: Zilganersen is currently under FDA review with a decision expected by September 22, and if approved, it will be the first disease-modifying treatment for Alexander disease, marking Ionis' first independent commercial launch in neurology.
- Positive Clinical Data: Zilganersen has demonstrated significant clinical benefits in pivotal studies, particularly in stabilizing gait speed, meeting its primary endpoint, which further reinforces its potential to transform the quality of life for patients with Alexander disease.
- Financial Gains: Under the agreement, Ionis will receive an upfront payment of $30 million and is eligible for additional milestone payments, with tiered royalties on annual net sales potentially reaching the mid-20% range, enhancing Ionis' financial outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 75.990
Low
65.00
Averages
92.67
High
110.00
Current: 75.990
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ionis Receives FDA Approval for TRYNGOLZA
- FDA Approval: Ionis' TRYNGOLZA (olezarsen) has received FDA approval as an adjunct to diet for reducing triglyceride levels and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG), marking the company's first independent commercial launch in a prevalent condition.
- Significant Efficacy: In the CORE and CORE2 studies, TRYNGOLZA demonstrated a triglyceride reduction of up to 72% at six months and a 91% reduction in acute pancreatitis events at 12 months, showcasing its strong clinical benefits, particularly in high-risk patients.
- Patient Benefits: Among patients treated with TRYNGOLZA, 86% achieved triglyceride levels below 500 mg/dL within 12 months, significantly lowering the risk of acute pancreatitis, indicating the drug's critical role in improving patient quality of life.
- Comprehensive Support Program: Ionis has launched the Every Step™ program to provide patients prescribed TRYNGOLZA with nutritional information, injection training, and insurance support, reflecting the company's commitment to enhancing patient health management.
See More
Ionis Pharmaceuticals Enters License Agreement with Recordati for Zilganersen
- License Agreement: Ionis Pharmaceuticals has entered into a licensing agreement with Recordati, granting the latter exclusive rights to develop and commercialize zilganersen outside the U.S., indicating a strategic expansion in global markets.
- U.S. Market Responsibility: Ionis will maintain sole commercial responsibility for zilganersen in the U.S., ensuring control in a key market and reinforcing its leadership in both development and marketing efforts.
- Regulatory and Commercial Support: Recordati will handle regulatory filings and commercialization outside the U.S., including country-specific support for early access pathways based on local regulations, enhancing the product's market access capabilities.
- Global Development Leadership: Ionis will continue to lead the global development of zilganersen, ensuring the product's adaptability and efficacy across different markets, thereby strengthening its competitive position in the rare disease sector.
See More
Ionis and Recordati Enter Exclusive License Agreement for Zilganersen
- Exclusive License Agreement: Ionis has entered into a licensing agreement with Recordati, granting Recordati exclusive rights to develop and commercialize zilganersen outside the U.S., while Ionis retains commercial responsibility in the U.S., indicating a strategic global market positioning for Ionis.
- FDA Review Progress: Zilganersen is currently under FDA review with a decision expected by September 22, and if approved, it will be the first disease-modifying treatment for Alexander disease, marking Ionis' first independent commercial launch in neurology.
- Positive Clinical Data: Zilganersen has demonstrated significant clinical benefits in pivotal studies, particularly in stabilizing gait speed, meeting its primary endpoint, which further reinforces its potential to transform the quality of life for patients with Alexander disease.
- Financial Gains: Under the agreement, Ionis will receive an upfront payment of $30 million and is eligible for additional milestone payments, with tiered royalties on annual net sales potentially reaching the mid-20% range, enhancing Ionis' financial outlook.
See More
FDA Approves Tryngolza for Severe Hypertriglyceridemia Treatment
- FDA Approval: The U.S. FDA approved Tryngolza on Wednesday as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, based on CORE and CORE2 trials showing up to 72% triglyceride reduction at six months.
- Commercial Launch: Ionis plans to launch Tryngolza in the U.S. in July, administered as a once-monthly subcutaneous injection at doses of 50 mg or 80 mg, which is expected to significantly enhance treatment options for over three million Americans suffering from this condition.
- Positive Stock Reaction: Following the FDA approval, Ionis Pharmaceuticals (IONS) shares rose 4% in after-hours trading, with Goldman Sachs raising its price target to $75, although this implies about a 2% downside from the current stock price, indicating optimistic market sentiment towards the new drug.
- Analyst Ratings: According to Koyfin, 21 out of 24 analysts covering IONS rated it as 'Buy' or higher, with an average price target of $104.91, suggesting a potential upside of approximately 37% from Wednesday's closing price, reflecting strong confidence in Tryngolza's market potential.
See More
FDA Approves New Indication for Ionis' Tryngolza
- FDA Approval: Ionis Pharmaceuticals' Tryngolza (olezarsen) has received FDA approval for reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, marking it as the first available therapy for this indication and representing a significant advancement in cardiovascular treatment.
- Market Potential: The approval opens new market opportunities for Ionis, particularly among patients with high triglyceride levels, which is expected to drive future revenue growth and enhance its competitive position in the biopharmaceutical industry.
- Previous Approval Context: Initially approved in 2024 for treating familial chylomicronemia syndrome, the expansion of Tryngolza's indication demonstrates its broad clinical application potential, further solidifying Ionis' leadership in innovative drug development.
- Positive Future Outlook: Following the FDA approval, Ionis plans to present its research findings at upcoming scientific conferences, which is anticipated to attract more investor interest and propel the company's ongoing development in the biopharmaceutical sector.
See More
Ionis Pharmaceuticals Appoints New Board Member
- New Board Member: Ionis Pharmaceuticals has appointed Ludwig Hantson to its Board of Directors, effective immediately, bringing over 30 years of leadership experience in the biopharmaceutical and medical device sectors, which will enhance the company's strategic direction.
- Rich Leadership Background: Hantson previously served as CEO and board member of Alexion from 2017 to 2021, a period marked by significant developments, particularly before its acquisition by AstraZeneca, showcasing his capability in navigating complex corporate environments.
- Strategic Development: CEO Brett P. Monia emphasized that Hantson's expertise in rare and specialty diseases will be invaluable as Ionis advances its commercial medicines and innovative pipeline, especially as the company enters a phase of accelerated growth and value creation.
- Stock Price Dynamics: Ionis's stock has fluctuated between $34.78 and $86.74 over the past year, currently trading at $74.17, down 0.42%, indicating a cautious market response to the company's new strategic direction.
See More
Ionis Receives FDA Approval for TRYNGOLZA
- FDA Approval: Ionis' TRYNGOLZA (olezarsen) has received FDA approval as an adjunct to diet for reducing triglyceride levels and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG), marking the company's first independent commercial launch in a prevalent condition.
- Significant Efficacy: In the CORE and CORE2 studies, TRYNGOLZA demonstrated a triglyceride reduction of up to 72% at six months and a 91% reduction in acute pancreatitis events at 12 months, showcasing its strong clinical benefits, particularly in high-risk patients.
- Patient Benefits: Among patients treated with TRYNGOLZA, 86% achieved triglyceride levels below 500 mg/dL within 12 months, significantly lowering the risk of acute pancreatitis, indicating the drug's critical role in improving patient quality of life.
- Comprehensive Support Program: Ionis has launched the Every Step™ program to provide patients prescribed TRYNGOLZA with nutritional information, injection training, and insurance support, reflecting the company's commitment to enhancing patient health management.
See More
Ionis Pharmaceuticals Enters License Agreement with Recordati for Zilganersen
- License Agreement: Ionis Pharmaceuticals has entered into a licensing agreement with Recordati, granting the latter exclusive rights to develop and commercialize zilganersen outside the U.S., indicating a strategic expansion in global markets.
- U.S. Market Responsibility: Ionis will maintain sole commercial responsibility for zilganersen in the U.S., ensuring control in a key market and reinforcing its leadership in both development and marketing efforts.
- Regulatory and Commercial Support: Recordati will handle regulatory filings and commercialization outside the U.S., including country-specific support for early access pathways based on local regulations, enhancing the product's market access capabilities.
- Global Development Leadership: Ionis will continue to lead the global development of zilganersen, ensuring the product's adaptability and efficacy across different markets, thereby strengthening its competitive position in the rare disease sector.
See More
Ionis and Recordati Enter Exclusive License Agreement for Zilganersen
- Exclusive License Agreement: Ionis has entered into a licensing agreement with Recordati, granting Recordati exclusive rights to develop and commercialize zilganersen outside the U.S., while Ionis retains commercial responsibility in the U.S., indicating a strategic global market positioning for Ionis.
- FDA Review Progress: Zilganersen is currently under FDA review with a decision expected by September 22, and if approved, it will be the first disease-modifying treatment for Alexander disease, marking Ionis' first independent commercial launch in neurology.
- Positive Clinical Data: Zilganersen has demonstrated significant clinical benefits in pivotal studies, particularly in stabilizing gait speed, meeting its primary endpoint, which further reinforces its potential to transform the quality of life for patients with Alexander disease.
- Financial Gains: Under the agreement, Ionis will receive an upfront payment of $30 million and is eligible for additional milestone payments, with tiered royalties on annual net sales potentially reaching the mid-20% range, enhancing Ionis' financial outlook.
See More
FDA Approves Tryngolza for Severe Hypertriglyceridemia Treatment
- FDA Approval: The U.S. FDA approved Tryngolza on Wednesday as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, based on CORE and CORE2 trials showing up to 72% triglyceride reduction at six months.
- Commercial Launch: Ionis plans to launch Tryngolza in the U.S. in July, administered as a once-monthly subcutaneous injection at doses of 50 mg or 80 mg, which is expected to significantly enhance treatment options for over three million Americans suffering from this condition.
- Positive Stock Reaction: Following the FDA approval, Ionis Pharmaceuticals (IONS) shares rose 4% in after-hours trading, with Goldman Sachs raising its price target to $75, although this implies about a 2% downside from the current stock price, indicating optimistic market sentiment towards the new drug.
- Analyst Ratings: According to Koyfin, 21 out of 24 analysts covering IONS rated it as 'Buy' or higher, with an average price target of $104.91, suggesting a potential upside of approximately 37% from Wednesday's closing price, reflecting strong confidence in Tryngolza's market potential.
See More
FDA Approves New Indication for Ionis' Tryngolza
- FDA Approval: Ionis Pharmaceuticals' Tryngolza (olezarsen) has received FDA approval for reducing triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, marking it as the first available therapy for this indication and representing a significant advancement in cardiovascular treatment.
- Market Potential: The approval opens new market opportunities for Ionis, particularly among patients with high triglyceride levels, which is expected to drive future revenue growth and enhance its competitive position in the biopharmaceutical industry.
- Previous Approval Context: Initially approved in 2024 for treating familial chylomicronemia syndrome, the expansion of Tryngolza's indication demonstrates its broad clinical application potential, further solidifying Ionis' leadership in innovative drug development.
- Positive Future Outlook: Following the FDA approval, Ionis plans to present its research findings at upcoming scientific conferences, which is anticipated to attract more investor interest and propel the company's ongoing development in the biopharmaceutical sector.
See More
Ionis Pharmaceuticals Appoints New Board Member
- New Board Member: Ionis Pharmaceuticals has appointed Ludwig Hantson to its Board of Directors, effective immediately, bringing over 30 years of leadership experience in the biopharmaceutical and medical device sectors, which will enhance the company's strategic direction.
- Rich Leadership Background: Hantson previously served as CEO and board member of Alexion from 2017 to 2021, a period marked by significant developments, particularly before its acquisition by AstraZeneca, showcasing his capability in navigating complex corporate environments.
- Strategic Development: CEO Brett P. Monia emphasized that Hantson's expertise in rare and specialty diseases will be invaluable as Ionis advances its commercial medicines and innovative pipeline, especially as the company enters a phase of accelerated growth and value creation.
- Stock Price Dynamics: Ionis's stock has fluctuated between $34.78 and $86.74 over the past year, currently trading at $74.17, down 0.42%, indicating a cautious market response to the company's new strategic direction.
See More
